PacWest Bancorp

PacWest Bancorp (Nasdaq: PACW), relating to its proposed sale to Banc of California, Inc. Under the terms of the agreement, PACW shareholders will receive 0.6569 shares of Banc of California per share they own.

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), relating to its proposed sale to Biogen, Inc. Under the terms of the agreement, RETA shareholders are expected to receive $172.50 in cash per share they own.

American National Bankshares Inc

American National Bankshares Inc. (Nasdaq: AMNB), relating to its proposed sale to Atlantic Union Bankshares Corp. Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.

New Relic, Inc.

New Relic, Inc. (NYSE: NEWR), relating to its proposed sale to Francisco Partners. Under the terms of the agreement, NEWR shareholders will receive $87.00 in cash per share they own.

Denbury, Inc.

Denbury, Inc. (NYSE: DEN), relating to its proposed sale to Exxon Mobil Corp. Under the terms of the agreement, DEN shareholders are expected to receive $89.45 in cash per share they own.

Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), relating to its proposed merger with Korro Bio, Inc. Under the terms of the agreement, FREQ shareholders are expected to own approximately 8% of the combined company

eMagin Corp.

eMagin Corp. (NYSE: EMAN), relating to its proposed sale to Samsung Display Co., Ltd. Under the terms of the agreement, EMAN shareholders are expected to receive $2.08 in cash per share they own.

Chase Corp.

Chase Corp. (NYSE: CCF), relating to its proposed sale to an affiliate of investment funds managed by KKR. Under the terms of the agreement, CCF shareholders are expected to receive $127.50 in cash per share they own.

Heritage-Crystal Clean, Inc.

Heritage-Crystal Clean, Inc. (Nasdaq: HCCI), relating to its proposed sale to an affiliate of J.F. Lehman & Co. Under the terms of the agreement, HCCI shareholders are expected to receive $45.50 in cash per share they own.

Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), relating to its proposed merger with Neurogene Inc. Under the terms of the agreement, NLTX shareholders are expected to own approximately 16% of the combined company.